Anixa Biosciences Inc
ANIX.OQ- Latest Trade
- trading lower2.98USD
- Change
- -0.08
- % Change
2.61%Negative
- Day Range
- 2.93 - 3.07
- 52-Week Range
- 2.34 - 5.86
As of Jul 3 2022. Values delayed up to 15 minutes
- Previous Close
- 3.06
- Open
- 3.05
- Volume
- 11,966.00
- 3 Month Average Trading Volume
- 1.88
- Shares Out (Mil)
- 30.47
- Market Cap
- 93.24
- Forward P/E
- -6.00
- Dividend Yield
- -99,999.99
Key Statistics
2 mean rating - 1 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- -99,999.99
- Price To Book (Quarterly)
- 2.87
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -45.51
- Return On Equity (TTM)
- -44.68
2021 (millions USD)
About Anixa Biosciences Inc
Company Information
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on oncology and infectious disease. The Company is developing chimeric endocrine receptor T-cell technology, a chimeric antigen receptor T-cell (CAR-T) technology focused on treating ovarian cancer, and anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. It is also developing vaccine against triple negative breast cancer (TNBC), the lethal form of breast cancer, and a vaccine against ovarian cancer. Its CAR-T technology can be used as a treatment against multiple solid tumor types. The Company’s segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics activities, and Patent Licensing activities. Its subsidiary Certainty Therapeutics, Inc. (Certainty), is developing immuno-therapy drugs against cancer.
Address
3150 Almaden Expy Ste 250SAN JOSE, CA
95118
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Amit Kumar
- Chairman of the Board, Chief Executive Officer
- Michael J. Catelani
- President, Chief Financial Officer, Chief Operating Officer
- Lewis H. Titterton
- Lead Independent Director
- Arnold Baskies
- Independent Director
- Emily Gottschalk
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,806.10 | 0.11%Positive |
| Copper | 679.40 | 2.12%Negative |
| Brent Crude Oil | 111.63 | -- |
| CBOT Soybeans | 1,622.00 | 3.16%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,825.33 | 1.06%Positive |
| Euro STOXX 50 | 3,448.31 | 0.19%Negative |
| FTSE 100 | 7,168.65 | 0.01%Negative |
| Nikkei 225 | 25,935.62 | 1.73%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes